tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Acadia Pharmaceuticals upgraded to Buy from Neutral at Guggenheim

Guggenheim analyst Yatin Suneja upgraded Acadia Pharmaceuticals to Buy from Neutral with a $22 price target.

Meet Your ETF AI Analyst

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on ACAD:

Disclaimer & DisclosureReport an Issue

1